evipedia.ai
← Back

Tetraselmis chuii for Health & Longevity

Evidence Review created on 08/25/2026 using AI4L / Opus 5

Also known as: TetraSOD, Oceanix, Tetraselmis chui

Motivation

Tetraselmis chuii is a single-celled green marine alga, grown in seawater tanks and dried into a dark green powder. It is sold as a food supplement because the cells are unusually rich in the enzymes living tissue uses to defend itself against oxygen damage. Interest centers on the idea that eating this biomass nudges the body’s own protective machinery rather than simply adding another antioxidant to the diet.

The alga has been farmed for decades as feed for shellfish and fish hatcheries. European regulators cleared it for human food in 2014 and for supplement use in 2017, and a handful of small human studies followed, mostly in athletes and in men attending fertility clinics. Almost all of that work involves the company that produces the ingredient.

This review examines what the published evidence shows about Tetraselmis chuii: which effects have been measured in people, how large and how reliable those measurements are, what is known about safety and product quality, and where the claims still rest on cell and animal work alone.

Benefits - Risks - Protocol - Conclusion

This section lists high-level sources that give a substantial overview of Tetraselmis chuii and the research behind its use as a supplement.

No content on Tetraselmis chuii was found on foundmyfitness.com, peterattiamd.com, hubermanlab.com, chriskresser.com, lifeextension.com or lifespan.io. Both web searches and direct site searches returned nothing for this microalga on any of the six priority platforms, so the list above is drawn entirely from the primary and review literature.

Grokipedia

Tetraselmis chui

Grokipedia’s fact-checked species entry, filed under the alternate spelling, covering taxonomy, cultivation, nutritional composition, the superoxide dismutase and catalase defences, and the 2014 European novel-food and 2016 US food-safety clearances.

Examine

Tetraselmis chuii

A short supplement entry describing the alga as rich in amino acids, essential fatty acids and micronutrients, with a linked research feed summarising the human body-composition trial and flagging its limitations.

ConsumerLab

No ConsumerLab article, product review or test report exists for Tetraselmis chuii. A direct search on 21 August 2026 returned no results, and the ingredient has never entered the organisation’s testing programmes.

Systematic Reviews

This section lists the pooled evidence bearing on the two sides of this intervention’s central trade-off: the claimed performance and recovery benefit of algal supplementation, and the counter-risk that sustained antioxidant intake blunts training adaptation.

Neither review covers this species; both entries above sit one step out from the ingredient, at the level of the supplement class. No systematic reviews or meta-analyses for Tetraselmis chuii were found on PubMed as of 21 August 2026.

Mechanism of Action

Tetraselmis chuii is grown under controlled light and salinity stress so that its cells accumulate high activity of superoxide dismutase — reported above 30,000 units per gram of freeze-dried biomass — together with catalase and glutathione peroxidase, two further enzymes that clear hydrogen peroxide.

The obvious explanation, that swallowed enzymes reach tissues and neutralise radicals directly, is not supported: these are large proteins, and simulated digestion degrades most of the biomass protein fraction (Paterson et al., 2024). The mechanism favoured by the ingredient’s investigators is indirect. Algal lipids, carotenoids and peptides — and possibly a mild pro-oxidant nudge — activate NRF2 (nuclear factor erythroid 2-related factor 2, the transcription factor that switches on the cell’s own antioxidant genes). A muscle-biopsy trial found higher resting expression of NRF2 itself, of glutathione peroxidase 7, glutathione reductase, glutathione S-transferase Mu 3 and peroxiredoxin 6, and of SIRT1 (sirtuin 1, a stress-response regulator that stabilises NRF2), alongside the signalling kinases p38 and ERK3 (Cocksedge et al., 2025). Genes encoding phospholipase A2, itself a source of reactive oxygen species, rose in parallel, which fits a hormetic reading: a small oxidative nudge provoking a larger defensive response.

A competing account attributes the observed effects not to enzyme signalling at all, but to the biomass’s omega-3 fatty acids, carotenoids and sulfated polysaccharides acting through ordinary lipid and immune pathways. The two are not mutually exclusive, and no human study has separated them.

Historical Context & Evolution

Tetraselmis chuii was described in 1959 from the Clyde Estuary in Scotland and spent its first four decades in aquaculture, not human nutrition. Hatcheries raising oysters, clams, scallops and shrimp larvae used it as live feed because the cells are easy to culture at high density and carry a favourable fatty acid profile. That industrial history is why a safety record in animals existed long before anyone proposed eating it.

The shift to human use came from a production observation rather than a clinical hypothesis. Fitoplancton Marino, a Spanish producer in Cádiz, found that manipulating light and salinity in closed photobioreactors pushed the cells to accumulate far higher superoxide dismutase activity than standard culture, and standardised the resulting freeze-dried biomass as TetraSOD. Spanish authorities cleared dried Tetraselmis chuii as a novel food in 2014; European rules extended that to food supplements up to 250 mg daily in 2017. Canada followed with its own novel-food clearance, and Lonza introduced the same biomass in North America as Oceanix in 2019.

Human research began only in 2020, and it began in sport. The first trials measured muscle damage and oxygen uptake (Sharp et al., 2020; Toro et al., 2020); hormonal, molecular and fertility work followed. Nothing in this history has been retracted or overturned — the literature is simply young, and its early positive direction has not yet been tested by anyone outside the commercial chain.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches this evidence level. There is no meta-analysis, no systematic review, and no large or independently replicated randomised trial of this ingredient.

Medium 🟩 🟩

Reduced Muscle Damage and Faster Recovery After Strenuous Exercise

Two randomised trials gave 25 mg daily for 14 days before a demanding exercise bout. Creatine kinase (CK, an enzyme that leaks from damaged muscle) stayed lower, jump power and isometric strength were better preserved, and salivary immunoglobulin A — a marker of mucosal immune defence that normally falls after heavy training — was maintained (Sharp et al., 2020; Sharp et al., 2021). Both were designed and part-funded by Lonza, which sells the ingredient as Oceanix, each enrolled about 20 people, and neither has been independently replicated.

Magnitude: Versus placebo 24–48 hours after a strenuous cross-training bout, serum creatine kinase was 14% lower, squat-jump power 15% higher, and the fall in maximal isometric strength 12% smaller (Sharp et al., 2020).

Higher Peak Oxygen Uptake

Peak oxygen uptake — the standard measure of aerobic fitness and one of the strongest predictors of long-term mortality — rose after supplementation in two separate trials, one a 14-day double-blind crossover with cycling to exhaustion, the other 30 days in amateur footballers (Cocksedge et al., 2025; Toro et al., 2020). The crossover trial’s increase was significant against its own baseline but not against placebo at the matched timepoint, and time to exhaustion did not improve significantly. Sample sizes were 13 and 32. The manufacturer co-authored the crossover trial.

Magnitude: End-exercise oxygen uptake rose from baseline after 14 days at 25 mg/day (p = 0.013, where p is the probability of seeing a result this large if the supplement did nothing), with no significant placebo-controlled difference; 30 days at 200 mg/day raised maximal oxygen consumption from 53.6 to 56.7 mL/kg/min in footballers (Toro et al., 2020).

Increased Expression of the Body’s Own Antioxidant Genes

A resting muscle biopsy taken after 14 days at 25 mg daily showed higher expression of NRF2 and of four enzymes it controls, plus SIRT1 (Cocksedge et al., 2025). Fold-changes were modest and variable, gene expression was not confirmed at protein level, and the effect was largest in people whose baseline expression was lowest — consistent with correction of a deficit rather than enhancement above normal.

Magnitude: Mean fold-changes versus placebo were 1.62 for NRF2, 1.73 for SIRT1 and 1.22–1.36 for glutathione peroxidase 7, glutathione reductase, glutathione S-transferase Mu 3 and peroxiredoxin 6, each with a standard deviation exceeding its mean (Cocksedge et al., 2025).

Low 🟩

In 80 men with unexplained infertility, 250 mg daily for three months raised luteinising hormone and progressive sperm motility, and cut sperm DNA fragmentation in those whose semen was oxidatively stressed at baseline (Leiva et al., 2026). Most comparisons were within-group; the manufacturer designed and funded the trial.

Magnitude: Luteinising hormone rose 17% and progressive motility 33% over three months; among men with abnormal seminal oxidation–reduction potential, sperm concentration roughly doubled, from 12.9 to 26.7 million per mL. Live births reached 66% versus 21% on placebo among the 49 couples with recorded outcomes (Leiva et al., 2026).

Small Shifts in Body Composition and Anabolic Hormones

Over 60 days, healthy young men taking 25 or 200 mg daily gained muscle percentage and lost fat percentage, with rises in free testosterone, insulin-like growth factor 1 (IGF-1, the main growth signal downstream of growth hormone) and erythropoietin (García et al., 2022). Diet was recorded only twice.

Magnitude: Over two months, muscle percentage rose from 47.4 to 48.9 and fat percentage fell from 13.0 to 11.1 at 25 mg/day, and from 47.1 to 48.3 and 13.4 to 11.1 at 200 mg/day, while placebo fat percentage rose from 12.8 to 13.9 (García et al., 2022).

Speculative 🟨

Gut Microbial Shift Toward Butyrate Production

Digested biomass in a laboratory colon model raised butyrate, Akkermansia and Butyricimonas while cutting Clostridium and Enterobacteriaceae (Majchrzak et al., 2025). Basis is in vitro only; no human stool data exist.

Improvement in Metabolic Syndrome Markers

Rats made obese on a cafeteria diet (unlimited palatable human snack foods) showed lower oxidised low-density lipoprotein and higher liver glutathione after eight weeks (Gil-Cardoso et al., 2022). Animal basis only; no human trial exists.

Skin Photoprotection

Vesicles isolated from the alga reduced ultraviolet-B damage, cellular senescence and melanin production in cultured human skin cells (Gargano et al., 2026). Mechanistic only, and tested as vesicles rather than the swallowed powder.

Neuroprotection of Nerve Cells

Extracts protected cultured neurons against glutamate and peroxide damage, and their carotenoids crossed a blood–brain barrier cell model (Cokdinleyen et al., 2025). Basis is cell culture only, using solvent extracts rather than the swallowed powder.

Benefit-Modifying Factors

  • Baseline redox status: Benefit tracks starting position. In the muscle-biopsy trial, participants with the lowest resting antioxidant gene expression showed the largest increases; in the fertility trial, only men with abnormal seminal oxidation–reduction potential gained sperm concentration.

  • Genetic polymorphisms: No pharmacogenetic data exist. Mechanistically, common variants in NFE2L2 (the gene encoding NRF2) and in KEAP1, its inhibitor, alter how strongly the antioxidant response fires, and could plausibly separate responders from non-responders.

  • Sex-based differences: Every human trial except the two exercise-recovery studies enrolled men only, and the fertility trial is male by design. Whether the hormonal and blood-count changes reported in young men occur in women is untested.

  • Pre-existing health conditions: Rat work showed the largest anti-inflammatory shifts against a background of diet-induced metabolic syndrome, implying that people carrying an existing metabolic or inflammatory burden may respond more than metabolically healthy ones.

  • Age: Trials ran in adults aged roughly 20–40. Endogenous antioxidant capacity and NRF2 signalling decline with age, so older adults are the group in which this mechanism would theoretically matter most, and the group with no data.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches this evidence level. A 90-day rat feeding study found no adverse effect at 2,500 mg/kg/day, roughly seven thousand times the human 25 mg dose on a body-weight basis, and no trial has reported a side effect attributable to the supplement (Mantecón et al., 2019).

Medium 🟥 🟥

Heavy Metal and Metalloid Accumulation in Algal Biomass

Microalgae concentrate whatever is in their culture water. An analysis of 15 commercial microalgal powders, including Tetraselmis chuii, found heavy-metal content varying strongly between and within species (Sandgruber et al., 2021), and this species converts inorganic arsenate into organic arsenic compounds (Irgolic et al., 1977). Closed photobioreactor production with batch certificates largely removes the exposure; open-pond or unbranded “marine phytoplankton” powders carry no such assurance. The risk is a property of the product, not of the species.

Magnitude: The single Tetraselmis chuii powder analysed carried 55.1 µg/100 g arsenic — fourth-highest of the fourteen powders tested, against a 70 µg/100 g organic-certification guideline — plus 0.59 µg/100 g cadmium, 0.40 mercury and 5.90 lead, all far below the European limits of 100, 10 and 300 (Sandgruber et al., 2021).

Low 🟥

Fall in Platelet Count and Mean Platelet Volume

Sixty days at 25 mg daily lowered platelet count, plateletcrit and mean platelet volume in healthy young men (García et al., 2022). The authors attribute this to the biomass’s long-chain omega-3 fats and carotenoids. Counts stayed within normal limits and no bleeding was reported.

Magnitude: At 25 mg/day, platelet count fell from 268.6 to 222.3 thousand per µL over two months — about 17%, against 7% in placebo — and was still 217.4 a month after stopping; mean platelet volume moved from 8.81 to 8.67 fL (García et al., 2022).

Rise in Circulating Insulin-Like Growth Factor 1

The same trial recorded higher insulin-like growth factor 1 at both doses (García et al., 2022). Marketed as an anabolic benefit, sustained elevation of this growth signal is weighted differently by a longevity-oriented reader, for whom mid-range rather than high values are usually the target.

Magnitude: By month two, insulin-like growth factor 1 rose from 253 to 362 ng/mL at 25 mg/day and from 261 to 383 ng/mL at 200 mg/day — roughly 43% and 47% — against 270 to 277 ng/mL in placebo (García et al., 2022).

Speculative 🟨

Blunting of Training Adaptations ⚠️ Conflicted

Chronic antioxidant intake can suppress the redox signalling that drives endurance adaptation (Wyckelsma et al., 2025; Pastor & Tur, 2019). This ingredient acts indirectly and may behave differently; untested across a training block.

Pro-Inflammatory Gene Activation in Liver Cells ⚠️ Conflicted

Freeze-dried biomass raised tumour necrosis factor alpha, interleukin 1 beta and interleukin 6 expression in cultured liver cells (Taroncher et al., 2023). Basis is in vitro only, opposite to the anti-inflammatory pattern reported in rats.

Unexplained Shifts in White Blood Cell Counts

White cell, neutrophil and lymphocyte counts rose over two months in supplemented men (García et al., 2022). Presented as immune stimulation, but a sustained rise has no established benefit; the proposed polysaccharide mechanism is untested.

Risk-Modifying Factors

  • Genetic polymorphisms: None identified for this ingredient. Variants in NFE2L2 and KEAP1 that amplify the antioxidant response would, in theory, also amplify any adaptation-blunting effect, making strong responders the group most exposed to the mechanistic downside.

  • Baseline biomarker levels: A platelet count already in the lower part of the reference range, or an insulin-like growth factor 1 already high for age, converts two otherwise trivial findings into reasons for closer tracking.

  • Sex-based differences: All hormonal and haematological safety observations come from young men. Women’s platelet counts run slightly higher on average, but no sex-stratified safety data exist for this supplement at any dose.

  • Pre-existing health conditions: Bleeding disorders, thrombocytopenia (a low platelet count), active liver disease and current cancer treatment are the conditions in which the platelet, hepatic-cell and antioxidant findings stop being academic. None has been studied.

  • Age: Older adults were absent from every trial. Age raises baseline bleeding risk and lowers platelet reserve, so the platelet finding carries more weight past 65 than in the 20-to-40-year-olds actually studied.

Key Interactions & Contraindications

  • Antiplatelet and anticoagulant drugs (aspirin, clopidogrel, warfarin, apixaban): Caution — the only trial measuring platelets found counts falling at 25 mg daily, and the biomass carries long-chain omega-3 fats, so an additive bleeding tendency is plausible. A platelet count at eight weeks covers it.

  • Vitamin K antagonists (warfarin, acenocoumarol): Caution. Green algal biomass contains vitamin K1, which opposes these drugs. At 25–250 mg of powder daily the absolute amount is trivial, but steady intake matters more than dose size; clotting-time checks at two and six weeks.

  • Over-the-counter anti-inflammatory drugs (ibuprofen, naproxen, aspirin): Caution. Both reduce platelet function, so the combination raises bruising and gastrointestinal bleeding risk slightly. Occasional use is unremarkable; daily use alongside the supplement warrants a platelet count.

  • Other antioxidant supplements (high-dose vitamin C, vitamin E, N-acetylcysteine, alpha-lipoic acid): Caution. Direct radical scavengers may cancel the mild oxidative signal this ingredient depends on, and high-dose vitamins C and E are the combination shown to blunt training adaptations. Separate cycles avoid the overlap.

  • Omega-3 supplements (fish oil, algal oil, krill oil): Additive. Both supply long-chain omega-3 fats and both lower platelet reactivity; the algal dose is tiny by comparison, so the practical effect is minor unless fish oil exceeds three grams daily.

  • Cytotoxic chemotherapy and radiotherapy: Absolute contraindication during treatment. Both work partly by generating reactive oxygen species, and an ingredient that upregulates antioxidant defences could shield target cells. No data exist either way; oncology teams routinely suspend antioxidant supplements during active treatment.

  • Other interventions (sauna, cold exposure, high-intensity interval training): Caution. All three work through mild stress signalling, and a supplement that raises baseline antioxidant capacity could in principle dampen the same signal. No study has tested the combination.

Populations who should avoid Tetraselmis chuii:

  • Pregnancy and breastfeeding — no human reproductive toxicity data, and the European authorisation covers adults only
  • Anyone under 18 — the European supplement authorisation is restricted to the adult population
  • Platelet count below 100 × 10⁹/L, or a diagnosed bleeding disorder such as haemophilia or von Willebrand disease
  • Scheduled surgery or dental extraction within 14 days
  • Active cytotoxic chemotherapy or radiotherapy, and the four weeks following a course
  • Known allergy to marine algae, or to the excipients used in a given capsule

Risk Mitigation Strategies

  • Batch-tested photobioreactor biomass only: Mitigates heavy-metal and arsenic exposure. A certificate of analysis on the finished powder should show total arsenic below 1 mg/kg, lead below 0.5 mg/kg and cadmium below 0.5 mg/kg.

  • Platelet count at eight weeks: Mitigates the observed fall in platelets and platelet volume. A drop below 150 × 10⁹/L, or new easy bruising, is the stopping signal; counts stayed below baseline a month after stopping.

  • Fourteen-day washout before surgery or dental extraction: Mitigates additive bleeding risk from the platelet effect combined with the omega-3 content, matching the standard withdrawal window used for fish oil.

  • A 25 mg daily ceiling outside fertility use: Mitigates the growth-signal rise. The 200 mg dose produced no additional benefit in the only dose-comparison trial while carrying the same hormonal changes.

  • Dosing confined to deload (planned reduced-training) and recovery weeks: Mitigates possible blunting of training adaptation. Dosing during recovery blocks rather than through a peak overload block leaves the exercise redox signal intact.

  • Insulin-like growth factor 1 recheck at twelve weeks: Mitigates unnoticed drift in a growth signal that longevity-oriented users track deliberately. A rise above mid-range for age is the trigger to cycle off.

Therapeutic Protocol

  • Standard dose: 25 mg daily of freeze-dried whole biomass — the dose used in every exercise trial, and the dose that outperformed 200 mg in the only comparison. Fertility protocols use 250 mg daily.

  • Competing approaches: Sports-nutrition practice uses 25 mg taken continuously; reproductive medicine uses 250 mg for one full three-month sperm cycle, then reassesses. The two protocols have never been compared head-to-head.

  • Who popularised each: Fitoplancton Marino in Cádiz developed the stress-cultivation process and the 25 mg positioning; Lonza brought the identical biomass to North America as Oceanix; the Hospital Clínic Barcelona group established the 250 mg fertility course.

  • Time of day: No timing study exists, and trials specified only once-daily dosing. Because the effect runs through gene expression rather than an acute action, timing is unlikely to matter; with a meal is preferred.

  • Half-life: Not a single compound, so no plasma half-life applies. The functional half-life is that of the induced gene expression: effects appeared within 14 days and had largely reversed three months after stopping.

  • Single versus split dosing: Untested and impractical. Both the 25 mg and the 250 mg protocols were delivered as one capsule once daily, and no trial has divided the dose.

  • Genetic polymorphisms: No pharmacogenetic testing has been done. Variants in NFE2L2 and KEAP1, which set how readily the antioxidant response fires, are the plausible candidates for separating responders from non-responders.

  • Sex-based differences: Dosing has never been sex-stratified. The hormonal and fertility results are male-only; the two exercise-recovery trials included women but did not analyse them separately.

  • Age-related considerations: Participants were roughly 20–40 years old throughout. No dose adjustment is established for older adults, though declining baseline antioxidant capacity argues for expecting more response, not less.

  • Baseline biomarker levels: Response tracked inversely with baseline antioxidant gene expression, and fertility gains were confined to men with elevated seminal oxidation–reduction potential. Measuring first is what distinguishes the two groups.

  • Pre-existing health conditions: Metabolic syndrome models showed the largest anti-inflammatory shifts, suggesting a higher inflammatory or metabolic burden predicts greater response. No trial has enrolled a clinical population outside fertility clinics.

Discontinuation & Cycling

  • Lifelong or short-term: Marketed as an ongoing daily supplement, but nothing in the data requires continuous use. The fertility protocol is explicitly a three-month course followed by reassessment rather than indefinite intake.

  • Withdrawal effects: None reported. In the fertility trial, sperm concentration and motility drifted back toward baseline within three months of stopping, without falling below starting values or producing any rebound symptom.

  • Tapering: Not applicable. No trial tapered, no withdrawal syndrome has been described, and the 25 mg dose already sits at the low end of what has been tested in humans.

  • Cycling: Untested, but two observations favour it. Sperm DNA integrity persisted after washout while other markers faded, and cycling off during heavy training blocks sidesteps the adaptation-blunting concern.

Sourcing and Quality

  • Production system: The biomass with human data behind it is grown in closed photobioreactors under controlled light and salinity stress, then freeze-dried. Open-pond or generic “marine phytoplankton” powders are a different product with different enzyme activity.

  • What to look for: A stated superoxide dismutase activity above 30,000 units per gram of freeze-dried biomass. Without that figure on the label or specification sheet, the product is generic Tetraselmis chuii powder rather than the tested ingredient.

  • Third-party testing: A batch certificate of analysis covering heavy metals, arsenic species, microbial counts and mycotoxins is the minimum, because microalgae concentrate whatever is present in the culture medium and the growth water.

  • Reputable suppliers: TetraSOD from Fitoplancton Marino in Cádiz and Oceanix from Lonza are the same biomass under two names. Finished retail products carrying the trial evidence name one of these on the label.

  • Formulation: Capsules and tablets are the only tested formats. Vitamin B12 measured below 0.02 mg per 100 g in every commercial microalgal powder analysed (Sandgruber et al., 2021), so an algal “whole-food B12” claim is unsupported.

Practical Considerations

  • Time to effect: Gene expression and blood markers shifted within 14 days, performance measures within 14–30 days, and semen parameters within three months, matching the length of one full sperm production cycle.

  • Common pitfalls: Buying generic Tetraselmis chuii or “marine phytoplankton” powder instead of the enzyme-standardised ingredient; assuming 200 mg outperforms 25 mg; and reading the vesicle and skin research as evidence for the swallowed powder.

  • Regulatory status: Authorised in the European Union as a novel food since 2014 and in food supplements up to 250 mg daily since 2017, cleared as a novel food in Canada, and sold in the United States as a dietary ingredient.

  • Cost and payer context: Roughly $30–60 for a three-month supply at 25 mg daily, and widely available online. No insurer or national health system reimburses it, so payer economics play no part in shaping its evidence base; manufacturer funding does.

Interaction with Foundational Habits

  • Sleep: No direct interaction. No trial measured sleep, and the biomass contains no stimulant or sedative compound. The plausible indirect route is through recovery — lower muscle damage after hard training reduces the night-time discomfort and elevated heart rate that fragment sleep. Dose timing relative to bedtime appears irrelevant.

  • Nutrition: Potentiating with dietary fat. The carotenoids and long-chain omega-3 fats that carry much of the activity are fat-soluble, so a meal containing fat improves absorption. Despite algal marketing, the powder supplies negligible vitamin B12 and does not replace a B12 source in plant-based diets.

  • Exercise: Direct and two-directional. Every performance finding required an exercise stimulus to appear, so the supplement does nothing measurable in sedentary use. The unresolved question is blunting: taking it through a heavy overload block may dampen the redox signal driving adaptation, which is why deload-week dosing is the cautious pattern.

  • Stress management: Indirect and unproven. Cortisol stayed flat in supplemented men while rising in placebo during a demanding exam period, which the authors attributed to omega-3 fats dampening adrenal steroid synthesis (García et al., 2022). An incidental within-group observation, not a designed measurement.

Monitoring Protocol & Defining Success

A baseline draw establishes the values this ingredient has been shown to move: a complete blood count with platelet indices, insulin-like growth factor 1, high-sensitivity C-reactive protein and gamma-glutamyl transferase. Where fertility is the goal, protocols add a semen analysis with sperm DNA fragmentation and, where available, seminal oxidation–reduction potential, since that measurement identified the responders in the randomised trial. A graded exercise test, or a validated wearable estimate of aerobic capacity, anchors the performance claim.

Because effects appear within two to four weeks and reverse within three months of stopping, monitoring suits a short cadence. The blood panel is commonly repeated at eight to twelve weeks, then every six to twelve months during continued use. Semen parameters need three months to reflect a full sperm production cycle, and aerobic testing is repeated at twelve weeks.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Platelet count 175–250 × 10⁹/L Tracks the one consistent blood change seen with this ingredient Ordered as part of a complete blood count. A fall below 150 × 10⁹/L is the stopping threshold; mean platelet volume is reported alongside
Insulin-like growth factor 1 100–160 ng/mL for adults over 40 Rose at both tested doses; longevity-oriented users prefer mid-range values Conventional laboratory ranges are age-banded and far wider, roughly 60–250 ng/mL. Fasting not required
High-sensitivity C-reactive protein Below 0.5 mg/L Background inflammation, the outcome the ingredient is marketed to improve hs-CRP is a blood test for low-grade inflammation. Conventional “low risk” cut-off is below 1.0 mg/L. Defer testing until two weeks after any infection
Gamma-glutamyl transferase 10–20 U/L (men), 8–15 U/L (women) Inexpensive proxy for glutathione turnover and oxidative load GGT is a liver enzyme. Conventional upper limits reach 50–60 U/L. Rises with alcohol, so intake should be recorded alongside
Total and free testosterone Total 600–900 ng/dL; free 15–25 ng/dL (men) Reported to rise at 25 mg/day and central to the fertility findings Draw between 07:00 and 10:00. Conventional lower limit is 264 ng/dL total, far below the functional target
Sperm DNA fragmentation Below 15% of sperm affected The clinical endpoint with a randomised outcome trial behind it Relevant only where fertility is the goal. A static oxidation–reduction potential above 1.34 mV per million/mL identified the men who responded
Haemoglobin and haematocrit Haemoglobin 14–15 g/dL (men), 13.5–14.5 g/dL (women); haematocrit 42–46% (men), 38–42% (women) Trials reported movement in red-cell indices in both directions Ordered with the platelet count. Conventional reference ranges are far wider — roughly 13.5–17.5 g/dL (men) and 12.0–15.5 g/dL (women) for haemoglobin. Hydration shifts haematocrit, so a single result should not be acted on
Peak oxygen uptake No established target; track change from the individual’s own baseline The performance outcome reported in two trials Requires a graded exercise test with gas analysis. A validated wearable estimate is an acceptable substitute for trend tracking

Qualitative markers worth tracking alongside the laboratory panel:

  • Day-after and second-day muscle soreness following a hard training session, the outcome with the most consistent trial support
  • Perceived recovery and readiness to train on consecutive days
  • Frequency of upper respiratory infections during heavy training blocks, matching the salivary immune finding
  • Easy bruising, gum bleeding or unusually long bleeding from small cuts, the practical counterpart to the platelet finding
  • Energy levels and perceived exertion at a fixed submaximal workload

Emerging Research

  • Ongoing dose-reduction fertility trial: NCT06324071, sponsored by Fitoplancton Marino and recruiting since 2024, is enrolling 50 men to test 125 mg daily — half the completed trial’s dose — against sperm motility, concentration and seminal oxidative stress.

  • Registered exercise trials now published: NCT06831656 and NCT06822556, both run at Loughborough University with 15 participants each, produced the oxygen-uptake and muscle gene-expression results (Cocksedge et al., 2025). No independent replication is registered.

  • Completed fertility trial awaiting replication: NCT04864314 enrolled 80 men and reported higher live birth rates (Leiva et al., 2026). Confirmation by an unaffiliated centre would strengthen the case; failure to replicate would weaken it substantially.

  • Vesicles as a separate product class: Vesicles isolated from the alga reduce ultraviolet-B damage and pigmentation in skin cells (Gargano et al., 2026). This is a cosmetic and drug-delivery line of work, not evidence for the swallowed powder.

  • Gut and antimicrobial directions: Digested biomass raised butyrate and Akkermansia in a colon model (Majchrzak et al., 2025); a companion proteomic study found peptides predicted to hit Helicobacter pylori targets but no measurable antibacterial effect (Majchrzak et al., 2025). Neither has been tested in people.

  • Evidence that could weaken the case: Fibre-type proteomics shows conventional antioxidants blunt sprint-training adaptations (Wyckelsma et al., 2025). No trial has checked whether an NRF2-activating microalga behaves differently across a full training block.

Conclusion

Tetraselmis chuii is a farmed marine alga sold as a small daily dose of dried whole cells, unusual for being rich in the enzymes living tissue uses to neutralise oxygen damage. The case for it does not rest on those enzymes surviving digestion. It rests on a subtler claim: that something in the biomass prompts the body to switch on its own protective genes more strongly. A muscle-tissue study, two exercise-recovery trials, a fertility trial and animal work all point loosely in that direction.

The evidence base is thin and closely held. Every trial is small, most compare each group against its own starting values rather than against a placebo group, and the company that makes the ingredient designed, funded or co-authored nearly all of them. No pooled analysis of the published work exists. Against that, the safety record is quiet: a long feeding study in animals found no harm at doses far above human intakes, European and Canadian regulators cleared it as a food, and no trial has reported a side effect.

Two findings sit awkwardly with a longevity-oriented reading of the same data. The growth signal that rose alongside the muscle and fat changes is one that many prefer to hold mid-range rather than push upward. And the drop in platelet numbers, small and within normal limits, has not been looked at in people already taking blood-thinning medication.

Top - Benefits - Risks - Protocol